Molecular therapy : the journal of the American Society of Gene TherapySep 7, 2025

A gene-engineered B cell treatment that maintains steady active factor IX levels for hemophilia B

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

BE-101 engineered B cells produced sustained active FIX-Padua in preclinical hemophilia B models and could be redosed.

Evidence

A preclinical engineered-cell study used CRISPR-Cas9 insertion of FIX-Padua into autologous B-lineage cells and found mouse FIX-Padua production within 1 day, steady state within 2 weeks, persistence beyond 184 days, near-linear redose response, and no off-target issues of concern in genotoxicity analyses.

Caveat

Durability, redosing, and safety are supported by animal tolerability and GLP toxicology studies, not by human hemophilia B outcomes.

Simplified

Hemophilia B gene therapy treatments have not addressed the need for predictable, durable, active, and redosable factor IX (FIX). Unlike conventional gene therapy, engineered B cell medicines (BCMs) are durable, redosable, and titratable and thus have the potential to address significant unmet needs in the hemophilia B treatment paradigm. BE-101 is an autologous BCM comprising expanded and differentiated B lymphocyte lineage cells genetically engineered ex vivo to secrete factor IX (FIX)-Padua. CRISPR-Cas9-mediated gene editing at the C-C chemokine receptor type 5 (CCR5) locus was used to facilitate transgene insertion of an adeno-associated virus 6-encoded DNA template via homology-directed repair. Transgene insertion did not alter B cell biology, viability, or differentiation into plasma cells. Appreciable levels of BE-101-derived FIX-Padua were detected within 1 day after IV administration in mice, and steady state was reached within 2 weeks and persisted for over 184 days. Redosing produced an increase in FIX-Padua production close to linear dose proportionality. Comprehensive genotoxicity analysis found no off-target issues of concern. No safety signals were observed in animal tolerability and Good Laboratory Practice toxicology studies. In conclusion, BE-101 produces sustained levels of active FIX-Padua with the ability to engraft without host preconditioning and with the potential for redosing and titratability.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of interests H.L., S. Singh, T.J.M., C.B., S.K., S.T., A. Lundberg, R.C., S.D., L.L. W.B., E.L., C.R.L., H.-M.C., R.K., A.F.H., S.P.A., A. Lazorchak, and R.A.M. reported being current employees at Be Biopharma. H.L., S. Singh, T.J.M., C.B., S.K., T.P., S.T., A. Lundberg, R.C., C.Y., S.D., L.L. W.B., E.L., C.R.M., C.R.L., T.K.O., S.C., H.-M.C., R.K., A.F.H., S.P.A., A. Lazorchak, and R.A.M. reported holding stock options in Be Biopharma, a privately held company. T.J.M., H.L., A.F.H., S.P.A., S. Singh, S.K., and R.A.M. are co-inventors of the patent “Engineered cell preparations for treatment of hemophilia” (WO2024220446A2).

PubMed

Featured in

CRISPR Gene EditingIssue #3

CRISPR fixes rare vascular disease in mice + new gene editing tools get safer

↗

A gene-engineered B cell treatment that maintains steady active factor IX levels for hemophilia B

Abstract

Full Text

Funding

Competing interests

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief

Abstract

Full Text

Funding

Competing interests

Related papers

Featured in

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief